HGEN News and Press, Humanigen Inc. From 08/05/20

Management presentation Monday, August 10 at 2:00 pm EDT Humanigen, Inc. , (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and b...

Conference call and webcast scheduled for today, August 3, 2020 at 4:30 pm EDT BURLINGAME, CA / ACCESSWIRE / August 3, 2020 / Humanigen, Inc. , (OTCQB:HGEN) ("Humanigen"), announced today that the Company will host an investor call and webcast to discuss the National Institute of Hea...

Shares of Humanigen (OTC: HGEN) , which were up 863% year to date through Monday's close, continued their upward momentum Tuesday after one of its monoclonal antibody drugs got an endorsement from scientists at the National Institutes of Health (NIH). The National Institute of Allergy and Inf...

Big Effect Trial (BET) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to advance high priority therapeutic candidates for COVID-19 Lenzilumab will be evaluated in combination with remdesivir and compared to placebo and remdesivir Humanigen...

Disclaimer: This report is the work of an investment adviser affiliated with the author. The report is the result of the adviser executing its investment strategy. The adviser holds a position in the security, however there is no assurance that the adviser will continue to hold the investm...

Humanigen ( OTCQB:HGEN ) expands its partnership with Catalent (NYSE: CTLT ) under which the latter will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s proprietary Humaneered anti-human granulocyte macrophage-colony stimulating...

Humanigen's investigational monoclonal antibody, lenzilumab, was developed using Catalent's proprietary GPEx ® cell line development technology Expanded partnership established product supply for lenzilumab, an investigational Phase 3 product for COVID-19 Catalent's OneBio &...

Humanigen ( OTCQB:HGEN ) has appointed  Dale Chappell as Chief Scientific Officer, David L. Tousley as Chief Accounting and Administrative Officer, Corporate Secretary and Treasurer and promoted Omar Ahmed to the position of Senior Vice President, Clinical, Medical ...

Dr. Dale Chappell appointed Chief Scientific Officer David Tousley appointed Chief Accounting Officer Dr. Omar Ahmed appointed Senior Vice President BURLINGAME, CA / ACCESSWIRE / July 7, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical-stage biopharmaceutic...

ZUMA-19 study being conducted as part of a clinical collaboration in the U.S. Study evaluating the potential effects of lenzilumab (anti-human-GM-CSF monoclonal antibody) prior to Yescarta® (axicabtagene ciloleucel) in adults with relapsed or refractory large B-cell lymphoma...